TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05500729

Intervention type: OTHER
Intervention: Hamstrings maximal voluntary isometric contraction.
Description: Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.

Intervention type: OTHER
Intervention: Hamstrings maximal voluntary isometric contraction.
Description: Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.

Intervention type: OTHER
Intervention: Quadriceps maximal voluntary isometric contraction
Description: Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.

Intervention type: OTHER
Intervention: Quadriceps maximal voluntary isometric contraction
Description: Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
Study: NCT05924009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation, TMS
Description: The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot.
Study: NCT05629559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: Single IV administration of 4D-310 Dose Level 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: Single IV administration of 4D-310 Dose Level 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: Single IV administration of 4D-310 Dose Level 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: Single IV administration of 4D-310 at the selected dose
Study: NCT05054088

Intervention type: DEVICE
Intervention: T-Detect COVID test
Description: • The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.

Intervention type: DEVICE
Intervention: T-Detect COVID test
Description: • The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
Study: NCT05584241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Disclosure Protocol
Description: Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomarker Disclosure Protocol
Description: Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
Study: NCT06509217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity Group
Description: Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Group
Description: Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
Study: NCT06335784

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene + Odor
Description: Sleep hygiene instructions will be applied in the presence of an odor, which will be also used during the night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention
Description: Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention
Description: Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention
Description: Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention
Description: Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.
Study: NCT05041283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone call
Description: A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
Study: NCT05947617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIX001
Description: This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIX001
Description: This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIX001
Description: This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes.
Study: NCT05090020

Intervention type: PROCEDURE
Intervention: Treatment
Description: Surgery and PAIR
Study: NCT05735860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
Study: NCT06541509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed.
Study: NCT05003752

Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiation therapy, High-dose-rate brachytherapy
Description: Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)

Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin 10.8 mg
Description: Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
Study: NCT06124716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced COACH CDS Tool
Description: CDS tool with features to promote high blood pressure management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care COACH CDS Tool
Description: CDS tool with limited features to promote high blood pressure management
Study: NCT04778397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously (IV).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroidal Eye Drops
Description: Administered per institutional standard during consolidation.
Study: NCT05419960

Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular Assessment
Description: During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)

Intervention type: DIAGNOSTIC_TEST
Intervention: Petrous bone Computed Tomography (CT)
Description: For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings.
Study: NCT06514001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study: NCT05659927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-ZG122 Humanized Monoclonal Antibody Injection
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-ZG122 Humanized Monoclonal Antibody Injection
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-ZG122 Humanized Monoclonal Antibody Injection
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-ZG122 Humanized Monoclonal Antibody Injection
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Study: NCT06069336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
Study: NCT04767009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
Description: Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
Study: NCT05705622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral mukositis nurse's education for patients
Description: Education given to patients by nurses on the prevention, treatment and care of oral mucositis
Study: NCT06008613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Holographic Guidance, Navigation, and Control (3D GN&C)
Description: Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2.
Study: NCT05395962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: treatment with bleomycin and carboplatin in association with electroporation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: treatment with bleomycin in association with electroporation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: treatment with bleomycin in association with electroporation
Study: NCT05289921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HU-014 Inj
Description: HU-014 Inj was given an injection to 5 Upper limb muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014 Inj
Description: HU-014 Inj was given an injection to 5 Upper limb muscle
Study: NCT05214976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)
Description: Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.